Rectal Cancer
Conditions
Brief summary
Neoadjuvant treatments (nCRT) are becoming the standard treatment for patients with stage II or stage III mid-low rectal cancer. In fact, with the introduction of total mesorectal excision, the local recurrence has been reduced significantly. Recently few studies have shown that surgery alone is enough for patients with T3 rectal cancer. These issues raised the question of whether nCRT is needed for all T3 rectal cancer patients. Therefore, this study was designed to compare the long-term oncological outcomes between surgery and surgery following nCRT among patients with MRI-defined T3, clear MRF mid-low rectal cancer.
Interventions
PROCEDUREtotal mesorectal excision
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Eighteen- to eighty-year-old patients. 2. T3 rectal cancer with clear mesorectal fascia (MRF), 3. within 12 cm from the anal verge at initial diagnosis by magnetic resonance imaging (MRI)
Exclusion criteria
1. emergency surgery due to bleeding, perforation, and bowel obstruction, 2. recurrent rectal cancer, 3. inflammatory bowel disease, 4. Stage IV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year diseases free survival | 3 years after surgery |
Secondary
| Measure | Time frame |
|---|---|
| Margin-free （R0）resection rate | Immediately after the surgery |
| 3-year overall survival rate | 3 years after surgery |
| Number of participants with surgical complications | 30 days after surgery |
| Local recurrence rate | 3 years after the surgery |
Outcome results
None listed